Circulating plasma tumor DNA

Heather A. Parsons, Julia Beaver, Ben H. Park

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Circulating cell-free DNA (ccfDNA)—first identified in 1947—is “naked” DNA that is free-floating in the blood, and derived from both normal and diseased cells. In the 1970s, scientists observed that patients with cancer had elevated levels of ccfDNA as compared to their healthy, cancer-free counterparts. The maternal fetal medicine community first developed techniques to identify the small fraction of fetal-derived ccfDNA for diagnostic purposes. Similarly, due to the presence of tumor-specific (somatic) variations in all cancers, the fraction of circulating cell-free plasma tumor DNA (ptDNA) in the larger pool of ccfDNA derived from normal cells can serve as extremely specific blood-based biomarkers for a patient’s cancer. In theory this “liquid biopsy” can provide a real-time assessment of molecular tumor genotype (qualitative) and existing tumor burden (quantitative). Historically, the major limitation for ptDNA as a biomarker has been related to a low detection rate; however, current and developing techniques have improved sensitivity dramatically. In this chapter, we discuss these methods, including digital polymerase chain reaction and various approaches to tagged next-generation sequencing.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages259-276
Number of pages18
Volume882
DOIs
StatePublished - 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume882
ISSN (Print)00652598
ISSN (Electronic)22148019

Fingerprint

Tumors
Plasmas
DNA
Neoplasms
Biomarkers
Blood
Plasmacytoma
Biopsy
Polymerase chain reaction
Tumor Burden
Medicine
Genotype
Mothers
Polymerase Chain Reaction
Liquids

Keywords

  • Breast cancer biomarker
  • Cancer biomarker
  • Circulating cell-free DNA
  • Digital PCR
  • Plasma tumor DNA
  • Tagged next-generation sequencing

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Parsons, H. A., Beaver, J., & Park, B. H. (2016). Circulating plasma tumor DNA. In Advances in Experimental Medicine and Biology (Vol. 882, pp. 259-276). (Advances in Experimental Medicine and Biology; Vol. 882). Springer New York LLC. https://doi.org/10.1007/978-3-319-22909-6_11

Circulating plasma tumor DNA. / Parsons, Heather A.; Beaver, Julia; Park, Ben H.

Advances in Experimental Medicine and Biology. Vol. 882 Springer New York LLC, 2016. p. 259-276 (Advances in Experimental Medicine and Biology; Vol. 882).

Research output: Chapter in Book/Report/Conference proceedingChapter

Parsons, HA, Beaver, J & Park, BH 2016, Circulating plasma tumor DNA. in Advances in Experimental Medicine and Biology. vol. 882, Advances in Experimental Medicine and Biology, vol. 882, Springer New York LLC, pp. 259-276. https://doi.org/10.1007/978-3-319-22909-6_11
Parsons HA, Beaver J, Park BH. Circulating plasma tumor DNA. In Advances in Experimental Medicine and Biology. Vol. 882. Springer New York LLC. 2016. p. 259-276. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-22909-6_11
Parsons, Heather A. ; Beaver, Julia ; Park, Ben H. / Circulating plasma tumor DNA. Advances in Experimental Medicine and Biology. Vol. 882 Springer New York LLC, 2016. pp. 259-276 (Advances in Experimental Medicine and Biology).
@inbook{1e2cff752ea94eb8bb29e83d34654497,
title = "Circulating plasma tumor DNA",
abstract = "Circulating cell-free DNA (ccfDNA)—first identified in 1947—is “naked” DNA that is free-floating in the blood, and derived from both normal and diseased cells. In the 1970s, scientists observed that patients with cancer had elevated levels of ccfDNA as compared to their healthy, cancer-free counterparts. The maternal fetal medicine community first developed techniques to identify the small fraction of fetal-derived ccfDNA for diagnostic purposes. Similarly, due to the presence of tumor-specific (somatic) variations in all cancers, the fraction of circulating cell-free plasma tumor DNA (ptDNA) in the larger pool of ccfDNA derived from normal cells can serve as extremely specific blood-based biomarkers for a patient’s cancer. In theory this “liquid biopsy” can provide a real-time assessment of molecular tumor genotype (qualitative) and existing tumor burden (quantitative). Historically, the major limitation for ptDNA as a biomarker has been related to a low detection rate; however, current and developing techniques have improved sensitivity dramatically. In this chapter, we discuss these methods, including digital polymerase chain reaction and various approaches to tagged next-generation sequencing.",
keywords = "Breast cancer biomarker, Cancer biomarker, Circulating cell-free DNA, Digital PCR, Plasma tumor DNA, Tagged next-generation sequencing",
author = "Parsons, {Heather A.} and Julia Beaver and Park, {Ben H.}",
year = "2016",
doi = "10.1007/978-3-319-22909-6_11",
language = "English (US)",
volume = "882",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "259--276",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Circulating plasma tumor DNA

AU - Parsons, Heather A.

AU - Beaver, Julia

AU - Park, Ben H.

PY - 2016

Y1 - 2016

N2 - Circulating cell-free DNA (ccfDNA)—first identified in 1947—is “naked” DNA that is free-floating in the blood, and derived from both normal and diseased cells. In the 1970s, scientists observed that patients with cancer had elevated levels of ccfDNA as compared to their healthy, cancer-free counterparts. The maternal fetal medicine community first developed techniques to identify the small fraction of fetal-derived ccfDNA for diagnostic purposes. Similarly, due to the presence of tumor-specific (somatic) variations in all cancers, the fraction of circulating cell-free plasma tumor DNA (ptDNA) in the larger pool of ccfDNA derived from normal cells can serve as extremely specific blood-based biomarkers for a patient’s cancer. In theory this “liquid biopsy” can provide a real-time assessment of molecular tumor genotype (qualitative) and existing tumor burden (quantitative). Historically, the major limitation for ptDNA as a biomarker has been related to a low detection rate; however, current and developing techniques have improved sensitivity dramatically. In this chapter, we discuss these methods, including digital polymerase chain reaction and various approaches to tagged next-generation sequencing.

AB - Circulating cell-free DNA (ccfDNA)—first identified in 1947—is “naked” DNA that is free-floating in the blood, and derived from both normal and diseased cells. In the 1970s, scientists observed that patients with cancer had elevated levels of ccfDNA as compared to their healthy, cancer-free counterparts. The maternal fetal medicine community first developed techniques to identify the small fraction of fetal-derived ccfDNA for diagnostic purposes. Similarly, due to the presence of tumor-specific (somatic) variations in all cancers, the fraction of circulating cell-free plasma tumor DNA (ptDNA) in the larger pool of ccfDNA derived from normal cells can serve as extremely specific blood-based biomarkers for a patient’s cancer. In theory this “liquid biopsy” can provide a real-time assessment of molecular tumor genotype (qualitative) and existing tumor burden (quantitative). Historically, the major limitation for ptDNA as a biomarker has been related to a low detection rate; however, current and developing techniques have improved sensitivity dramatically. In this chapter, we discuss these methods, including digital polymerase chain reaction and various approaches to tagged next-generation sequencing.

KW - Breast cancer biomarker

KW - Cancer biomarker

KW - Circulating cell-free DNA

KW - Digital PCR

KW - Plasma tumor DNA

KW - Tagged next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=84961653107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961653107&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-22909-6_11

DO - 10.1007/978-3-319-22909-6_11

M3 - Chapter

C2 - 26987539

AN - SCOPUS:84961653107

VL - 882

T3 - Advances in Experimental Medicine and Biology

SP - 259

EP - 276

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -